Upfront Briefing
Novo Nordisk’s oral Wegovy is showing strong early prescription uptake just two weeks after launch — a quick reminder that “oral” is a feature, not a footnote.
Sanofi is still planning an FDA filing for amlitelimab in eczema despite mixed Phase 3 results, opting for regulatory reps over a redo.
And Merck reportedly walked from a $25B+ Revolution Medicines bid over price — a reminder that even in "must-buy" oncology, megacap buyers are staying disciplined.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,915.6 |
0.0% |
+1.0% |
| Nasdaq 100 |
25,605.5 |
+0.3% |
+1.4% |
| Russell 2000 |
2,669.2 |
(1.8%) |
+7.5% |
| XBI (Biotech ETF) |
128.0 |
(2.7%) |
+5.0% |
| Nasdaq Biotech |
5,936.7 |
(1.4%) |
+4.0% |
| Clinical Trials ETF (BBC) |
42.8 |
(2.6%) |
+10.9% |
|
-
Risk appetite narrowed into a catalyst-heavy week: small caps sold off (Russell (1.8%)) while megacap tech held up (Nasdaq 100 +0.3%).
-
Biotech underperformed on the same "risk-off" impulse: XBI (2.7%) and NBI (1.4%) vs S&P flat.
-
Market data: U.S. close Jan 23, 2026.
The Big 3
|
1
|
Novo Nordisk's oral Wegovy shows strong early uptake
|
- Novo Nordisk's oral Wegovy pill is seeing strong early prescription uptake just two weeks after its market launch, according to analysts.
- Why it matters: Early script velocity de-risks the "oral convenience" thesis and pulls forward the key debate for investors: how quickly payers cover, how much injectable Wegovy is cannibalized vs expanded demand, and what it implies for competitive timelines in oral incretins (especially as next-gen oral assets try to justify premium valuation on differentiation).
- Source: Endpoints
- More: Fierce Pharma; BioPharma Dive
|
|
2
|
Sanofi plans FDA filing for eczema drug despite mixed data
|
- Sanofi intends to seek FDA approval for amlitelimab in eczema, despite reporting mixed results from its Phase 3 trials.
- Why it matters: This is a high-stakes "regulatory strategy" tell: Sanofi is trying to convert mixed Phase 3s into a label anyway, because amlitelimab is part of the post-Dupixent immunology growth narrative. For investors, the swing factors are label breadth, differentiation vs entrenched AD standards, and whether a constrained label forces a slower/cheaper launch curve than the Street is underwriting.
- Source: BioPharma Dive
- More: Endpoints; BioSpace
|
|
3
|
Merck reportedly ends Revolution Medicines deal talks
|
- Merck is reportedly no longer in talks to acquire Revolution Medicines after a price disagreement, per WSJ (via Reuters).
- Why it matters: This is a sentiment read for 2026 M&A: even in "must-buy" oncology, mega-cap buyers appear price-disciplined. It also warns investors not to underwrite rumor premiums as durable comps — particularly ahead of RVMD's upcoming clinical catalysts.
-
Source:
Reuters
-
More:
WSJ
|
Everything Else that broke
- FDA accepts LEQEMBI subcutaneous sBLA for early Alzheimer's under Priority Review. — PR
- Moderna alters vaccine trial plans due to anti-vaccine sentiment and policy changes. — Fierce Pharma
- ACIP chair comments spark scrutiny after vaccine schedule change. — Endpoints
- Bausch Health's Xifaxan successor fails Phase 3 trial. — Fierce Pharma
- EU launches pilot (FAST-EU) to speed multinational clinical trial starts. — Endpoints
- Priority review voucher program debate continues, with a report suggesting rare disease biotechs could lose $4B if it's not reinstated. — BioSpace
- Congress and insurers clash over healthcare consolidation and affordability. — BioPharma Dive
- F2G outlines FDA resubmission plans for olorofim after Phase 3 data. — Endpoints
- Novartis CEO discusses expanding presence in RNAi, with de-risking as a core mantra. — BioCentury
- Ilona Reischl re-elected as EMA CAT chair. — EMA
Deal Flow
M&A / BD&L
-
Process update: Merck is reportedly no longer in talks to buy Revolution Medicines after a price disagreement (per WSJ/Reuters). —
Reuters
/ WSJ
-
ST Pharm inks $56M API manufacturing deal for a US biotech's oligonucleotide treatment. —
Fierce Pharma
-
Reporting suggests Lilly was the only pharma bidder for Ventyx. —
Endpoints
VC / Private Financings
-
Quiet weekend on disclosed private rounds (no major new financings vs Friday's tape). If you saw one we missed, reply — we'll add it to the tracker.
IPOs / Follow-Ons
- Corvus closes upsized public offering (gross proceeds ~ $201M) with full exercise of underwriters' option. — PR
- Erasca closes upsized public offering of common stock. — PR
- Strong follow-on demand may signal IPO appetite. — BioCentury
Academic Corner
-
Quiet weekend on new translational reads — we’ll be back when the journals drop something spicy.
|
